Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials

被引：0
|
作者：
Ibrahim Elmakaty
Ruba Abdo
Ahmed Elsabagh
Abdelrahman Elsayed
Mohammed Imad Malki
机构：
[1] QU Health,College of Medicine
[2] Qatar University,Pathology Unit, Department of Basic Medical Sciences, College of Medicine
[3] QU Health,undefined
[4] Qatar University,undefined
来源：
Cancer Cell International | / 23卷
关键词：
PD-1/PD-L1 inhibitors; Immune checkpoint inhibitors; Overall survival; Progression-free survival; Pathological complete response; Adverse events; Efficacy; Safety; Systematic review; Network meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials
    Elmakaty, Ibrahim
    Abdo, Ruba
    Elsabagh, Ahmed
    Elsayed, Abdelrahman
    Malki, Mohammed Imad
    CANCER CELL INTERNATIONAL, 2023, 23 (01)
  • [2] Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis
    Zhang, Meilin
    Song, Jian
    Yang, Hongguang
    Jin, Feng
    Zheng, Ang
    ACTA ONCOLOGICA, 2022, 61 (09) : 1105 - 1115
  • [3] A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer
    Wang, Chaoyang
    JOURNAL OF ONCOLOGY, 2022, 2022
  • [4] The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis
    Xiao, Bo-Ya
    Lin, Guo-He
    Zhao, Yan-Xia
    Wang, Bi-Cheng
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (06) : 3804 - 3818
  • [5] Efficacy and Safety of PD-1/PD-L1 Inhibitors in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
    Li, Zhen-Yu
    Zhang, Zhen
    Cao, Xiao-Zhong
    Feng, Yun
    Ren, Sha-Sha
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2023, 50 (09):
  • [6] Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis
    Huang, Ya-Fang
    Xie, Wen-Jie
    Fan, Hai-Yu
    Du, Juan
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [7] Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
    Zhenzi Wang
    Yuan Liu
    Kedi Wang
    Liyan Ma
    BMC Gastroenterology, 24 (1)
  • [8] PD-L1 expression as biomarker of efficacy of PD-1/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: A systematic review and meta-analysis
    Khan, Muhammad
    Du, Kunpeng
    Ai, Meiling
    Wang, Baiyao
    Lin, Jie
    Ren, Anbang
    Chen, Chengcong
    Huang, Zhong
    Qiu, Wenze
    Yuan, Yawei
    Tian, Yunhong
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [9] Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials
    Li, Shan
    Sun, Shanquan
    Xiang, Hui
    Yang, Jing
    Peng, Minyong
    Gao, Qing
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [10] Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
    Zhang, Yixi
    Wang, Jingyuan
    Hu, Taobo
    Wang, Huina
    Long, Mengping
    Liang, Baosheng
    LIFE-BASEL, 2022, 12 (12):
12345